Optimal candidates and surrogate endpoints for HAIC versus Sorafenib in hepatocellular carcinoma: an updated systematic review and meta-analysis

医学 索拉非尼 肝细胞癌 荟萃分析 内科学 危险系数 科克伦图书馆 子群分析 肿瘤科 经导管动脉化疗栓塞 人口 胃肠病学 置信区间 外科 环境卫生
作者
Tengfei Si,Qing Shao,Wayel Jassem,Yun Ma,Nigel Heaton
出处
期刊:International Journal of Surgery [Wolters Kluwer]
标识
DOI:10.1097/js9.0000000000001889
摘要

Background and Aims: Hepatic artery infusion chemotherapy (HAIC) has been a long-standing intervention for hepatocellular carcinoma (HCC). Despite positive clinical outcomes, its inclusion in guidelines remains limited due to a lack of evidence-based support. This study aims to identify optimal target populations for HAIC and validate associations between intermediate endpoints with overall survival (OS). Methods: Following PRISMA guidelines, a comprehensive search was conducted in PubMed, Embase, Cochrane Library, and Web of Science. The primary search strategy was based on medical subject headings terms (MeSH) using “Hepatic arterial infusion chemotherapy”, “HAIC”, “Sorafenib”, “Nexavar”, “hepatocellular carcinoma”, “HCC”, “Liver cancer”, combined with free text words. Data extraction, quality assessment, and analysis were performed according to pre-registered protocol. Results: A total of 26 studies, 6456 HCC patients were included for analysis (HAIC, n=2648; Sorafenib, n=3808). Pooled outcomes revealed that Sorafenib demonstrated better OS only in patients who were refractory to trans-arterial chemoembolization (TACE) (HR=1.32,95%CI [1.01-1.73]), in other subgroups or overall HCC population HAIC consistently outperformed Sorafenib in patients’ survival. Radiologically, higher response rates in the HAIC group does not necessarily translate into survival improvement, but the hazard ratios (HRs) of 1y-OS (R 2 =0.41, P =0.0044) and 1y-progression free survival (1y-PFS) (R 2 =0.77, P =0.0002) strongly correlated with the patients OS. Meanwhile, larger tumour size (HR=1.86,95%CI [1.12-3.1, 95%), heavier tumour burden (HR=2.32, 95%CI [1.33-4.02), existence of MVI or EHS (HR=1.65,95%CI[1.36-2]; HR=1.60,95%CI[1.19-2.14]), and AFP >400 ng/mL (HR=1.52, 95%CI [1.20-1.92]) were identified as independent risk factors for OS, while HAIC treatment (HR=0.54, 95%CI[0.35-0.82]) and lower BCLC stage (HR=0.44, 95%CI[0.28-0.69]) were potential protective factors for HCC patients. Conclusion: HAIC monotherapy appears noninferior to Sorafenib in HCC treatment, with potential benefits in specific subgroups. The robust correlation between 1y-OS/1y-PFS and OS, alongside identified risk and protective factors from the present study, offers valuable insights for designing future large prospective studies in this field.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
希望天下0贩的0应助王某采纳,获得10
刚刚
NPC-CBI完成签到,获得积分10
1秒前
wonder123发布了新的文献求助30
2秒前
vv完成签到,获得积分10
2秒前
2秒前
2秒前
畅快芾完成签到,获得积分10
2秒前
3秒前
Mo发布了新的文献求助50
4秒前
phoenix完成签到,获得积分10
4秒前
ding应助干净又晴采纳,获得10
5秒前
虚拟的怀绿完成签到,获得积分10
5秒前
krisliu完成签到,获得积分10
5秒前
舍予有服发布了新的文献求助10
7秒前
酷波er应助老迟到的梦旋采纳,获得10
7秒前
7秒前
畅快芾发布了新的文献求助10
8秒前
小周完成签到,获得积分10
10秒前
田様应助jiajia采纳,获得10
11秒前
Hello应助zjs采纳,获得10
12秒前
ttong发布了新的文献求助10
12秒前
12秒前
ablesic.rong完成签到,获得积分10
13秒前
sml发布了新的文献求助10
13秒前
cutey小鲸鱼完成签到,获得积分20
14秒前
you完成签到,获得积分10
15秒前
krisliu发布了新的文献求助10
16秒前
YJ888发布了新的文献求助10
17秒前
干净又晴发布了新的文献求助10
18秒前
18秒前
jason完成签到,获得积分20
19秒前
小磊完成签到,获得积分10
20秒前
20秒前
赘婿应助周健采纳,获得10
24秒前
haocheng完成签到,获得积分20
24秒前
Mark完成签到 ,获得积分10
25秒前
lzx发布了新的文献求助10
25秒前
26秒前
26秒前
传奇3应助gogoyoco采纳,获得10
26秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989550
求助须知:如何正确求助?哪些是违规求助? 3531774
关于积分的说明 11254747
捐赠科研通 3270278
什么是DOI,文献DOI怎么找? 1804966
邀请新用户注册赠送积分活动 882125
科研通“疑难数据库(出版商)”最低求助积分说明 809176